Dr Chattopadhyay: What are the key selling points of the UK for biosimilar trials?

The UK is a unique place to deliver clinical research. As part of Europe, we are approximately ten years ahead of the US in acceptance and adoption of biosimilars. But what really gives us a competitive edge, is our National Health Service and the government-funded research infrastructure embedded within it through the National Institute for Health Research (NIHR). We asked Dr Chattopadhyay, NHS Rheumatologist and clinical investigator: What are the key selling points of the UK as a destination for biosimilar clinical trials?